Radioligand Therapies Market Size, Share & Industry Analysis, By Product (Lutetium Lu 177 Vipivotide Tetraxetan, Lutetium Lu 177 Dotatate, and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors, and Others), By Target (Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor, and Others), By End User (Tertiary Care Academic/Comprehensive Cancer Centers, Specialized Nuclear Medicine Centers, and Others), and Regional Forecast, 2026-2034

ATTRIBUTE

DETAILS

Study Period

2021-2034

Base Year

2025

Estimated Year

2026

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 27.51% from 2026-2034

Unit

Value (USD Billion)

Segmentation

By Product, Indication, Target, End User, and Region

By Product

·         Lutetium Lu 177 Vipivotide Tetraxetan

·         Lutetium Lu 177 Dotatate

·         Others

By Indication

·         Prostate Cancer

·         Neuroendocrine Tumors

·         Others

By Target

·         Prostate-Specific Membrane Antigen (PSMA)

·         Somatostatin Receptor

·         Others

By End User

·         Tertiary Care Academic/Comprehensive Cancer Centers

·         Specialized Nuclear Medicine Centers

·         Others

By Region

·         North America (By Product, Indication, Target, End User, and Country)

o   U.S.

o   Canada

·         Europe (By Product, Indication, Target, End User, and Country/Sub-Region)

o   Germany

o   U.K.

o   France

o   Spain

o   Italy

o   Scandinavia

o   Rest of Europe

·         Asia Pacific (By Product, Indication, Target, End User, and Country/Sub-Region)

o   China

o   Japan

o   India

o   Australia

o   Southeast Asia

o   Rest of Asia Pacific

·         Latin America (By Product, Indication, Target, End User, and Country/Sub-Region)

o   Brazil

o   Mexico

o   Rest of Latin America

·         Middle East & Africa (By Product, Indication, Target, End User, and Country/Sub-Region)

o   GCC

o   South Africa

o   Rest of the Middle East & Africa